Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
NCT ID NCT07695896
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study looks at how well a drug called glofitamab (a bispecific antibody) works for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are observing about 200 adults in China who are already receiving this drug as part of their regular care. The goal is to see how many patients have their tumors shrink or disappear, and to track any side effects, providing real-world evidence on the drug's effectiveness and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab (a bispecific antibody)
- What this could lead to
- If successful, this study could show that bispecific antibodies like glofitamab are effective and safe for treating relapsed or refractory B-cell non-Hodgkin lymphoma in everyday clinical practice, potentially offering a new treatment option.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. The treatment may not work for everyone, and side effects are possible. The study is also limited to a Chinese population, which may not generalize globally.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets Hard-to-Treat lymphoma in early human test
- New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
- New hope for tough cancers: experimental drug LP-284 enters human testing
- Engineered immune cells take on childhood blood cancers in early trial
- New combo aims to tackle tough lymphomas
- New antibody drug YK012 takes aim at Hard-to-Treat lymphoma